恆瑞醫藥(600276.SH):提名聘任廖成為公司副總經理
格隆匯 10 月 19日丨恆瑞醫藥(600276.SH)公佈,公司第八屆董事會第七次會議決議,審議通過《關於提名聘任廖成先生為公司副總經理的議案》;
根據公司經營發展需要,現提名聘任廖成為公司副總經理,其個人簡歷如下:
廖成,男,1975年生,1993-1997年在北京大學生命科學院學習,獲得理學學士學位。1997年進入中國科學院上海生物化學與細胞生物學研究所,並於2002年7月獲得理學博士學位。2002年9月至2006年8月在美國耶魯大學醫學院從事博士後研究。2006年至2012年在羅氏製藥擔任資深研究員,從事創新藥物的研發工作。2013年在德國默克公司工作,任資深研究員,項目負責人。2014至2015年8月在艾伯維醫藥公司,領導腎病領域創新藥物的研發和轉化研究。2015年9月至2017年在美國強生醫藥公司,負責肺癌的轉化醫學研究。2018年1月加入恆瑞醫藥,任子公司副總經理,分管臨牀前開發、轉化醫學與對外研發等事務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.